Inhibitor Therapeutics, Inc. Stock Price

OTCPK:INTI Community·US$8.6m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

INTI Share Price Performance

US$0.05

-0.04 (-41.18%)

US$0.05

-0.04 (-41.18%)

US$0.05

Sun, 9 Nov 25

Share PriceUS$0.05

INTI Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

0 Rewards

View Full Analysis

Inhibitor Therapeutics, Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.02
: 0%
: 0%
: 0%

View Full Analysis

About INTI

Founded: 1992
Employees: 6
CEO: Francis O'Donnell
WebsiteView website: inhibitortx.com

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.